Ahn-Gook Pharmaceutical Co. Ltd Cash Flow Conversion Efficiency
Ahn-Gook Pharmaceutical Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, Ahn-Gook Pharmaceutical Co. Ltd (001540) has a cash flow conversion efficiency ratio of 0.086x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩14.44 Billion ≈ $9.79 Million USD) by net assets (₩167.29 Billion ≈ $113.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ahn-Gook Pharmaceutical Co. Ltd (2012–2024)
Cash flow conversion efficiency of Ahn-Gook Pharmaceutical Co. Ltd from 2012 to 2024. This chart illustrates how Ahn-Gook Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Ahn-Gook Pharmaceutical Co. Ltd for real-time trading data and today's change.
Ahn-Gook Pharmaceutical Co. Ltd Cash Flow Conversion Ratio Explained
Ahn-Gook Pharmaceutical Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ahn-Gook Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ahn-Gook Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency. Also see Ahn-Gook Pharmaceutical Co. Ltd (001540) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
I&C Technology Co. Ltd
KQ:052860
|
-0.009x |
|
Mnc Investama Tbk
JK:BHIT
|
0.006x |
|
5E Advanced Materials Inc
AU:5EA
|
-0.057x |
|
Huadian Ener-B
SHG:900937
|
0.052x |
|
Hanjin Heavy Ind & Const Holdings Co Ltd
KO:003480
|
0.039x |
|
Huikwang
TWO:6508
|
0.041x |
|
Can One Bhd
KLSE:5105
|
0.088x |
|
Igis Residence Reit Co Ltd
KO:350520
|
N/A |
Annual Cash Flow Conversion Efficiency for Ahn-Gook Pharmaceutical Co. Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Ahn-Gook Pharmaceutical Co. Ltd from 2012 to 2024. Review 001540 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩165.68 Billion ≈ $112.28 Million |
₩4.91 Billion ≈ $3.33 Million |
0.030x | +438.78% |
| 2023-12-31 | ₩151.67 Billion ≈ $102.78 Million |
₩-1.33 Billion ≈ $-899.86K |
-0.009x | -175.78% |
| 2022-12-31 | ₩154.80 Billion ≈ $104.90 Million |
₩1.79 Billion ≈ $1.21 Million |
0.012x | +14.00% |
| 2021-12-31 | ₩145.26 Billion ≈ $98.44 Million |
₩1.47 Billion ≈ $997.66K |
0.010x | -86.95% |
| 2020-12-31 | ₩144.10 Billion ≈ $97.65 Million |
₩11.19 Billion ≈ $7.58 Million |
0.078x | -47.86% |
| 2019-12-31 | ₩148.25 Billion ≈ $100.46 Million |
₩22.08 Billion ≈ $14.96 Million |
0.149x | +1919.68% |
| 2018-12-31 | ₩146.77 Billion ≈ $99.46 Million |
₩-1.20 Billion ≈ $-814.03K |
-0.008x | -106.42% |
| 2017-12-31 | ₩136.96 Billion ≈ $92.81 Million |
₩17.46 Billion ≈ $11.84 Million |
0.128x | +32.23% |
| 2016-12-31 | ₩130.89 Billion ≈ $88.70 Million |
₩12.62 Billion ≈ $8.55 Million |
0.096x | -33.85% |
| 2015-12-31 | ₩131.06 Billion ≈ $88.82 Million |
₩19.11 Billion ≈ $12.95 Million |
0.146x | +1287.76% |
| 2014-12-31 | ₩122.46 Billion ≈ $82.99 Million |
₩1.29 Billion ≈ $871.80K |
0.011x | -63.54% |
| 2013-12-31 | ₩126.42 Billion ≈ $85.67 Million |
₩3.64 Billion ≈ $2.47 Million |
0.029x | -71.39% |
| 2012-12-31 | ₩114.36 Billion ≈ $77.50 Million |
₩11.51 Billion ≈ $7.80 Million |
0.101x | -- |
About Ahn-Gook Pharmaceutical Co. Ltd
Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.